Since 1998, the Swiss Biotech Association (SBA) has represented the interests of the Swiss biotech industry in Switzerland and abroad. The Swiss biotech industry is one of the most innovative and successful industries.
Currently, more than 15,000 employees are directly engaged in Swiss biotech companies and additional 40,000 indirect jobs in suppliers and service providers contribute to the success of Swiss biotech sector.
To further strengthen its resources and network, the SBA has appointed Dr Patrick Amstutz (CEO of Molecular Partners) and Filippo Riva (CEO of Humabs Biomed) at its General Assembly as new board members and has announced the appointment of Dr Michael Altorfer (former CEO of Polyphor) as its new CEO, effective 1 January 2018.
Dr Dominik Escher, President of the SBA, said: “ Filippo Riva and Patrick Amstutz represent the classical biotech companies from private to public and from more early stage to late stage development. We are very glad to strengthen our board through their experience, personal network of international industry contacts and deep understanding of the needs and strengths of the Swiss biotech industry.
“Michael Altorfer has more than 20 years of experience in the Swiss life science industry and operational know-how at all management levels. I would like to welcome Michael as the new CEO of the Swiss Biotech Association. With his deep industry experience, he is best positioned to move the Association forward.”
Michael Altorfer said: “The Swiss biotech companies play a crucial role in discovering and developing new innovative technologies, diagnostics, medicine and healthcare treatment options. They work in close collaboration with their network of industry partners, including leading Swiss universities, hospitals and innovative technology and service suppliers, to address the most pressing medical needs. The SBA is dedicated to supporting them in this effort and to help creating an environment in which these companies can work effectively.”
